Exploring the perceptions of advanced practitioner radiographers at a single breast screening unit in extending their role from delivering benign to malignant biopsy results; a preliminary study
Author(s) Eden J.K.; Borgen R.
Source The British journal of radiology; Sep 2020 ; p. 20200423
OBJECTIVE: The study aims to explore the perceptions of Advanced Practice Radiographers (APRs) currently giving benign biopsy results to extend their role to deliver NHS Breast Screening Programme (NHSBSP) malignant outcomes. In the UK, APRs are appropriately trained to deliver results, yet traditionally have been cultured not to. Increasing pressures on NHSBSP units are a key driver for APR evolvement. A significant lack of published research provides the rationale for the study, combined with an identified service need.
Radiation protection value to the operator from augmented reality smart glasses in interventional fluoroscopy procedures using phantoms
Author(s) Dorey S.; Gray L.; Tootell A.; Higgins R.; Hogg P. et al.
Source Radiography; Nov 2019; vol. 25 (no. 4); p. 301-307
Introduction: Smart glasses can be adapted to display radiographic images to allow clinician's gaze not to be directionally fixed or predetermined by computer monitor location. This study presents an analysis of eye lens dose during interventional fluoroscopy guided procedures, comparing fixed monitor positions against the use of smart glasses.
Method(s): Using a head phantom (simulating the clinician), thermoluminescent dosimeters and lead shielded glasses, the dose to the eye was measured for different head 'rotations and tilts' for: gaze directed towards the main scattering source (patient/primary beam) to represent potential gaze direction if smart glasses are used; gaze directed to a range of potential computer monitor positions. An anthropomorphic pelvis phantom was utilised to simulate the patient. Accumulated dose rates (muGy s1) from five 10-second exposures at 75 kV 25.2 mAs were recorded.
Result(s): An average DAP reading of 758.84 cGy cm2 was measured during each 10 second exposure. Whilst wearing lead shielded glasses a 6.10 - fold reduction in dose rate to the lens is possible (p < 0.05). Influence of the direction of gaze by the clinician demonstrated a wide range of dose rate reduction from 3.13% (p = 0.16) to 143.69% (p < 0.05) when the clinician's gaze was towards the main scattering source. Increased dose rate to the clinician's eyes was received despite wearing lead shielded glasses, as the angle of gaze moved 45degree and 90degree from 0degree.
Conclusion(s): If the clinician's gaze is directed towards the main scattering source a potential exists for reducing eye lens dose compared with fixed location computer monitors. Introduction of lead lined smart glasses into interventional radiology may lead to improvements in patient care, reducing the need for the clinician to look away from the patient to observe a radiographic image.Copyright © 2019
Author(s): Hujazi I.; Yassa R.; Sevenoaks H.; Khalfaoui M.; Barrie J.
Source: Foot and Ankle Surgery; Aug 2019; vol. 25 (no. 4); p. 507-510
Publication Date: Aug 2019
Publication Type(s): Article
Available at Foot and Ankle Surgery - from ClinicalKey
Abstract:Background: Reliable radiographic measurement of hallux valgus interphalangeus (HVI) deformity has a role in guiding surgical management. HVI can be assessed using: * Hallux interphalangeal angle (HIA). * Distal articular set angle (DASA). * Proximal to distal phalangeal articular angle (PDPA). The aim of the study is to investigate the reliability of these radiological parameters.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Author(s): Parker C.C.; Dearnaley D.P.; James N.D.; Brawley C.D.; Ritchie A.W.S.; Gilson C.; Langley R.E.; Millman R.; Amos C.L.; Parmar M.K.B.; Sydes M.R.; Clarke N.W.; Hoyle A.P.; Ali A.; Tran A.T.H.; Attard G.; Chowdhury S.; Cross W.; Gillessen S.; Jones R.J.; Russell J.M.; Malik Z.I.; Eswar C.; Mason M.D.; Matheson D.; Thalmann G.N.; Alonzi R.; Bahl A.; Birtle A.; Din O.; Douis H.; Gale J.; Gannon M.R.; Jonnada S.; Khaksar S.; Lester J.F.; O'Sullivan J.M.; Parikh O.A.; Pedley I.D.; Pudney D.M.; Sheehan D.J.; Srihari N.N.
Source: The Lancet; Dec 2018; vol. 392 (no. 10162); p. 2353-2366
Publication Date: Dec 2018
Publication Type(s): Article
Abstract:Background: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy. Method(s): We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer.
The following databases were searched:
EMBASE, MEDLINE, PsycINFO, BNI, CINAHL,
to find ELHT staff publications
Archives - past 2 years
Your Specialty or Professional Group
Membership Terms & Conditions